

Market Breaks Out On Vaccine Hopes As Cases Surge



In this issue of "Market Breaks Out On Vaccine Hopes As Cases Surge."

- *Market Breaks Out Barely*
- *Vaccine Will Arrive Too Late*
- *The "Smart Money" Is Leaving Town*
- *Portfolio Positioning Update*
- *MacroView: The Fed Will Monetize All Debt Issuance*
- *Sector & Market Analysis*
- *401k Plan Manager*

Follow Us On: [Twitter](#), [Facebook](#), [Linked-In](#), [Sound Cloud](#), [Seeking Alpha](#)

Join Me Virtually For The MoneyShow

Please join me for a presentation on *"How To Invest When Markets*

Detach From The Economy." November 19th @ 10 am EST / 9 am CST
Register Now to reserve your spot.



MONEYSHOW®
VIRTUAL EXPO

STREAMING LIVE
NOVEMBER 17-19, 2020


**HOW TO INVEST WHEN
MARKETS ARE DETACHED
FROM THE REAL ECONOMY**

LANCE ROBERTS | *Real Investment Report*

REGISTER FREE >>

A portrait of Lance Roberts, a man with short brown hair, smiling, wearing a dark blue button-down shirt. The background of the banner is dark blue with faint white and orange geometric patterns and a line graph.

Catch Up On What You Missed Last Week



#WhatYouMissed On RIA This Week: 11-13-20

Written by Lance Roberts | Nov 13, 2020

Here is what you might have missed from the RIA Crew last week. A compilation of our best blogs, newsletter, podcasts, the daily radio show and commentary from RIAPRO.NET.

[**>> Read More**](#)

Market Breaks Out - Barely

If you like volatility, then this past week was for you. On Monday, the announcement by Pfizer sent markets screaming higher. However, it wasn't like rallies we had seen previously. Instead, it was a fierce rotation from the previous leaders to laggards. Nonetheless, the market initially surged to all-time highs immediately following the news. But as we will discuss in a moment, the news wasn't really what it seemed. Subsequently, the market faded into the end of the day. The rotation to value turned out to be very short-lived as markets returned to the reality of rising Coronavirus cases and no "stimulus" on the horizon. Since the highs of September, the market is now just 0.50% higher today. Like I said, if you like volatility, you have gotten a good dose of it.



Yes, It's Still A Sellable Rally

Importantly, we had stated last week, the stock market rally had already gotten ahead of itself. To wit:

*"However, before you get all excited and go throwing your money into the market, you may want to step back and re-evaluate your risk. **If you haven't liked the ups and***

downs in the market over the last couple of months, you have too much 'risk' in your portfolio. Furthermore, while we did expect this rally and added exposure in our portfolios, the previous 'oversold' condition has now been largely reversed. As shown below, the market is now back to more 'overbought' conditions, which suggests limited upside from current levels. Also, the deviation from the 200-dma is now back to levels that have previously led to mild, short-term corrections."

Chart updated through Friday:



The rally from the October lows was a "sellable rally." The current rally is as well. Given the more overbought condition, we expect a one to two-week correction at the beginning of December as mutual funds make their annual distributions. **While it is feasible, the markets will end the year positively; we will likely see a better entry point first.** However, there is the problem of the surge in virus cases as we head into year-end.



Real Investment Show
with Lance Roberts

Monday to Friday,
from 6 to 7am. [Get it now](#)

Vaccine Will Arrive Too Late

"Vaccine news" is certainly good and very welcome. However, do not get overly excited. Since the [coronavirus emerged in January](#), almost 200 vaccine candidates have gone into development.

Only 15 got to human trials, and there are no approvals for use. The odds of creating a successful vaccine are very low, and most vaccines fail before production. While Pfizer's vaccine, so far, seems to be moving along the path, there are several things to consider. Foremost is that while Pfizer did announce the potential effectiveness of their vaccine, it is yet to be peer-reviewed or approved for use by the FDA. While the drug is on a "fast-track" for use by year-end for emergency use, it [will not be available for widespread use anytime soon.](#) To wit:

"But the vaccine's complex and super-cold storage requirements are an obstacle for even the most sophisticated hospitals in the United States and may impact when and where it is available in rural areas or poor countries where resources are tight.

*The main issue is that the vaccine, which is based on a novel technology that uses synthetic mRNA to activate the immune system against the virus, **needs to be kept at minus 70 degrees Celsius (-94 F) or below.**"*

Furthermore, they are only in Phase-3 of their drug trials. As noted, a very high percentage of drugs fail in Stages 3 and 4. Pfizer will have to start Phase IV once the FDA approves the drug. That phase will incorporate testing the drug in limited use on several hundred or thousands of patients. This phase will take quite some time to accomplish, and if unknown side-effects appear, it could stop the production of the vaccine altogether.

Not As Easy As It Sounds

Lastly, even if Pfizer gets through Phase-IV and begins to produce the drug, and solves the "freezer" problem, it is unlikely to be seen by most of the population for many months. As noted by the [Wall Street Journal](#):

"However, it could be many [months before any vaccine is administered to enough people](#) to ease the need for lockdown measures that have been recently reimposed across the West. Duke Global Health Innovation Center estimates that **there won't be enough vaccines to cover the world's population until 2024.**


Of course, such also assumes you can get people to get vaccinated.

"While previous vaccination programs have spread over years and focused on specific demographics such as children or the elderly, governments are hoping to do something they never have done before and inoculate a majority of the population in a matter of months. Even for rich nations with developed vaccination programs, that presents a host of problems including building new databases to track who is getting the shot, working out ways to encourage mass uptake [among younger people](#), ensuring adequate supply and running large-scale inoculation centers where the shots can be safely and quickly administered. Those challenges mean that even if a vaccine is soon approved, it could be many months before it is administered to enough people to ease the need [for lockdown measures](#) that have been recently reimposed across the West." - [WSJ](#)

Shutdowns Aren't The Solution.

For the markets, the race against time is likely already lost. There is currently "no stimulus" bills in progress in Congress. The "virus" is surging across the country, with cities once again calling for

lockdowns and reversals of opening progress. Such is very bad economically and will further delay openings. As discussed yesterday in our ["3-Minutes."](#) another shutdown would be economically damaging and would not solve the pandemic. <https://www.youtube.com/watch?v=oys4GbTJQQ0> As noted, the pandemic's surge, shutdowns, and lack of stimulus are terrible for corporate earnings and, ultimately, the market. With markets extraordinarily overbought and deviated from long-term means, the risk of a correction is more than elevated. **Notably, the rotation to "value" is likely premature as these companies specifically require a more robust economy to generate revenue and earnings growth.** The current environment is not conducive to that. Expect a reversal of the trade soon, and money rotates back towards "pandemic" related companies.



Such is also why the "Smart Money" has already been exiting the market.

RIAPro


Get the latest trades, analysis, and insights from the **RIA Pro** team.

[> Sign up now](#)

The Smart Money Is Leaving Town

If you haven't checked out [RIAPro \(30-day Risk-Free Trial\)](#), we provide a daily market commentary on what is happening. On Thursday, Mike Lebowitz posted an essential piece.

"Bloomberg's Smart Money Flow Index is a measure of how 'smart money' is positioning itself in the S&P 500. The logic behind the index is that smart investors tend to trade near the end of the day, while more emotional-based traders dominate activity in the first 30 minutes of the trading day. The index is calculated as follows: yesterday index level ? the opening gain or loss + change in the last hour. As shown below, the Smart Index and the S&P were well correlated until late August. Since then, as highlighted by the red arrow, they have diverged sharply. Over the last ten years, the S&P 500 and the Smart Index have a strong correlation of .65. **As such, we expect they will converge in time.** The light blue circle shows they also diverged, albeit to a much lesser extent, in January and February as the smart money correctly sensed problems."




Yields Have It

"The graph below compares 10 year UST yields versus 10 implied breakeven inflation rates. The current gap between the two is relatively wide but even wider, considering that UST yields are usually higher than the inflation rate, not lower. **In other words, real rates are negative.** If the economy is going to fully recover, we should expect the UST yield to gravitate to and above the inflation rate. If that were to happen, it would imply 10-year yields of approximately 1.50-2.00%. **We do not think the odds of that occurring are high because such ?high? rates would heavily weigh on the economy. It is more than likely the Fed continues to aggressively buy bonds to keep yields much lower than where they should be.** The other way the gap potentially closes is if the market has inflation expectations wrong and the implied inflation rate falls. **Such a scenario suggests the recovery falters.**"




"Finally, the graph above shows the two components used to calculate real yields. As shown above, the blue line (UST yield) has made recent progress toward closing the gap with inflation expectations, ie real rates are now less negative. The next graph shows the strong negative correlation between the level of real rates (blue line) and the price of gold. **If real rates continue to rise and become less negative or even positive, we should expect the price of gold to suffer, and vice versa if real rates reverse the recent trend.**"



Mom & Pop Finally Turn Optimistic

As noted, while "Smart Money" is leaving town, the bullishness of retail investors has finally spiked to the highest level in years. Such is months after the recovery from the lows. Historically, such has also been an excellent short-term contrarian indicator.

"The percentage of bulls in the American Association of Individual Investors (AAII) survey rose to 55.8% while bears dropped to 24.9%, pushing the Bull Ratio, a more accurate measure of optimism, above 69%. The last 2 times it got this high, stocks ended up running into trouble eventually." - SentimenTrader



As Bob Farrell once quipped:

"Investors buy the most at the top, and the least at the bottom."

Real Investment Report

Market updates, sector analysis, 401k plan manager & more.

> [Subscribe today](#)

Portfolio Positioning Update

When the market does things that are entirely unexpected, irrational, or just plain illogical, such is any living organism's behavior. The stock market is just that. The wild rotation from growth to value and back again was undoubtedly one of the unexpected events. Our job is to adjust our allocations to capture these rotations when trends are changing as portfolio managers. **However, the difficult part is knowing the difference between a "kneejerk reaction" and a "trend change."** On Monday, we decided to remain with our allocations, which already has some "value" to allow the market time to play out. That decision proved correct as our portfolio's growth portion quickly came back into play after a rough couple of days. More importantly, we took the opportunity to buy Treasury bonds, which got deeply oversold and 3-standard deviations below their moving average, as shown in the chart below. Such deep oversold conditions rarely last for long and generally lead to decent trading opportunities. That additional bond exposure played out well for the remainder of the week.



What's The Biggest Mistake Investors Make?

My friend and trading colleague Victor Adair penned a great note last week:


*"Interest rates are currently the lowest they've been in hundreds of years. In the early 1980s, people could get 13% interest on a bank account, but now 'high interest' accounts pay less than half a percent. You might say that it's wrong for savers to suffer because the Central Bank has cut interest rates to zero to support the economy. I'd agree, but the fact is that ultra-low interest rates have forced many otherwise cautious people into taking a little more risk to earn a decent return on their investments. **When people believe that they need to take 'a little more risk' to generate greater returns, they may be making a very BIG mistake if they underestimate what 'risk' really means to them.**"*

His point is incredibly important. As we noted in "[Moral Hazard](#)," the Federal Reserve believes that insuring people against investment losses is a dangerous one. While investors are encouraged to take more risk currently, as prices rise, they begin to disregard risk for what it is. When people take a little risk and get rewarded for it, they are then encouraged to take a little more risk. As Victor notes, **"People in the 'crowd' don't appreciate the risks they are taking because they're surrounded by people who believe the market will keep going up."**

What Is The Risk??

"One way to measure 'risk' in today's markets is to think of it as the difference between current market prices and the price where 'value investors' like Howard would start buying. Believe me; the difference is HUGE." - Victor Adair. The incredible stock market rally of the last 40 years has occurred while falling interest rates have forced more and more people to shift from being savers to being investors. It's not just the stock market. Virtually all asset prices have gone up as interest rates have tumbled. When there is no hurdle rate to the cost of money, then a lot of money gets invested poorly. There are very few bargain-priced assets these days. As Victor notes, if we are indeed in another stock market bubble, then valuations don't matter much. The only thing that matters is confidence, and if people are confident that the market will keep going higher, it will until something triggers a "loss of confidence."


Main Stages in a Bubble



*"In a bull market, the Fear Of Missing Out (FOMO) is so strong that people see marketing schemes such as ?passive investing? as brilliant ideas. They willingly sign up to have money clipped off their paycheck and invested in the stock market every month, **regardless of price**. They do this because they have chosen to believe (or have been sold on the idea) that stock prices will only go higher." - Victor Adair*

Manage The Risk

Victor is correct when he states **there has been much irrational exuberance in the past few years. Along with that exuberance, asset prices got bid aggressively higher.** There is nothing wrong with that except that the "**risk of loss**" from these levels is much greater now. It is essential to have a strategy and discipline that can minimize downside volatility. If you don't have one, then work with your investment advisor to assess your portfolio, risk, and risk tolerance. Decide if it is time to make portfolio changes. If not, then make plans to reduce risk systematically if the market starts to fall. That way, you won't panic and make *?spur of the moment?* decisions if the market takes a tumble. If you don't have a disciplined investment strategy and are just part of the crowd, here are 10-rules of risk management to get you thinking. How you chose to manage your portfolio is up to you. However, over the long-term, being aggressive without acknowledging the risks has tended not to work out well over time.

**REAL
INVESTMENT
ADVICE**

Have more than \$500k invested?
Get a better strategy than
"buy and hold"

**MEET WITH AN
RIA TEAM
MEMBER TODAY**

The MacroView



#MacroView: Is The Fed Stuck With "Forever Stimulus?"

Written by Lance Roberts | Nov 13, 2020

I recently discussed the "Importance of Recessions" and how "Rescues Ruining Capitalism." While the data is clear that ongoing stimulus programs lead to weaker economic growth and rising wealth gap, is the Fed stuck with "forever stimulus?"


[>> Read More](#)

If you need help or have questions, we are always glad to help. [Just email me.](#) See You Next Week **By Lance Roberts, CIO**

Market & Sector Analysis

Analysis & Stock Screens Exclusively For RIAPro Members

S&P 500 Tear Sheet




Performance Analysis




Technical Composite

The technical overbought/sold gauge comprises several price indicators (RSI, Williams %R, etc.), measured using "weekly" closing price data. Readings above "80" are considered overbought, and below "20" is oversold.



Portfolio Positioning "Fear / Greed" Gauge

The "Fear/Greed" gauge is how individual and professional investors are "positioning" themselves in the market based on their equity exposure. From a contrarian position, the higher the allocation to equities, to more likely the market is closer to a correction than not. The gauge uses weekly closing data.



Sector Model Analysis & Risk Ranges

How To Read.

- The table compares each sector and market to the S&P 500 index on relative performance.
- The "MA XVER" is determined by whether the short-term weekly moving average crosses positively or negatively with the long-term weekly moving average.
- The risk range is a function of the month-end closing price and the "beta" of the sector or market.
- The table shows the price deviation above and below the weekly moving averages.

RELATIVE PERFORMANCE		Current	PERFORMANCE RELATIVE TO S&P 500 INDEX					SHORT	LONG	MONTH	REL S&P	RISK RANGE		% DEV -	% DEV -	M/A XVER
Ticker	ETF NAME	Price	1 Week	4 Week	12 Weeks	24 Weeks	52 Weeks	WMA	WMA	END PRICE	BETA	HIGH	LOW	Short M/A	Long M/A	SIGNAL
IVV	ISHARS-SP500	359.34	2.25	3.13	5.42	17.75	14.58	342.30	316.54	327.62	0.99	335.81	319.43	5%	14%	BULLISH
XLB	SPDR-MATLS SELS	69.01	(0.76)	1.01	6.08	6.71	(0.25)	64.81	58.41	63.18	1.07	65.44	60.92	6%	18%	BULLISH
XLC	SPDR-COMM SV SS	64.11	(1.60)	2.35	0.11	0.93	8.73	60.93	55.87	59.20	0.99	61.27	57.13	5%	15%	BULLISH
XLE	SPDR-EGY SELS	33.88	14.86	9.10	(11.39)	(30.34)	(58.19)	32.20	34.86	28.72	1.63	29.91	27.53	5%	-3%	BEARISH
XLF	SPDR-FINL SELS	27.03	6.05	5.04	5.76	(2.28)	(23.72)	24.82	23.68	23.86	1.15	24.73	22.99	9%	14%	BULLISH
XLK	SPDR-TECH SELS	121.20	(2.56)	(3.06)	(2.66)	5.96	24.35	117.51	105.26	110.86	1.07	114.82	106.90	3%	15%	BULLISH
XLI	SPDR-INDU SELS	85.76	3.19	1.97	6.75	8.99	(10.39)	78.86	71.27	75.87	1.14	78.63	73.11	9%	20%	BULLISH
XLP	SPDR-CONS STPL	67.53	1.50	(1.07)	(0.40)	(3.73)	(4.47)	64.76	61.22	62.26	0.57	64.17	60.35	4%	10%	BULLISH
XLRE	SPDR-RE SELS	37.51	3.03	0.75	(0.94)	(9.49)	(17.28)	35.87	34.75	34.15	0.70	35.24	33.06	5%	8%	BULLISH
XLU	SPDR-UTIL SELS	66.09	0.81	0.14	5.80	(7.02)	(9.43)	61.42	59.26	62.38	0.35	64.16	60.60	8%	12%	BULLISH
XLV	SPDR-HLTH CR	112.12	(0.25)	0.77	(0.46)	(8.90)	0.46	106.42	102.18	101.66	0.78	105.00	98.32	5%	10%	BULLISH
XLY	SPDR-CONS DISCR	153.45	(1.80)	(2.73)	(0.45)	5.81	11.85	148.82	132.32	142.97	1.17	148.21	137.73	3%	16%	BULLISH
XTN	SPDR-SP TRANSP	66.34	5.41	5.38	7.57	9.34	(11.82)	60.59	54.37	58.57	1.36	60.83	56.31	9%	22%	BULLISH
SDY	SPDR-SP DIV ETF	103.60	5.34	3.36	3.09	(3.69)	(17.04)	95.90	91.61	92.46	0.87	95.57	89.35	8%	13%	BULLISH
RSP	INVS-SP5 EQ ETF	120.05	3.06	2.74	4.46	1.46	(7.93)	111.27	103.33	107.51	1.10	111.38	103.64	8%	16%	BULLISH
SLY	SPDR-SP6 SC	70.89	5.26	4.66	5.97	6.40	(13.05)	64.12	59.18	62.33	1.24	64.66	60.00	11%	20%	BULLISH
MDY	SPDR-SP MC 400	385.62	2.08	2.81	5.22	2.19	(8.88)	353.45	326.99	346.27	1.18	359.00	333.54	9%	18%	BULLISH
EEM	ISHARS-EMG MKT	48.33	(1.41)	2.95	3.72	10.35	(2.53)	45.16	41.36	44.71	0.87	46.22	43.20	7%	17%	BULLISH
EFA	ISHARS-EAFE	69.37	2.52	4.03	2.26	(1.43)	(13.04)	64.82	61.30	61.39	0.81	63.42	59.36	7%	13%	BULLISH
IAU	ISHARS-GOLD TR	18.00	(5.53)	(3.73)	(8.02)	(8.85)	13.71	18.29	17.39	17.89	0.08	18.35	17.43	-2%	4%	BULLISH
GDX	VANECK-GOLD MNR	38.01	(10.48)	(7.69)	(12.47)	(7.00)	27.56	40.04	36.71	37.49	0.73	38.70	36.28	-5%	4%	BULLISH
UUP	INVS-DB US\$ BU	25.03	(1.69)	(4.15)	(6.02)	(23.65)	(21.22)	25.18	25.95	25.37	(0.11)	25.98	24.76	-1%	-4%	BEARISH
IXUS	ISHARS-CR INT S	63.25	0.83	2.96	2.27	2.04	(10.07)	59.44	55.40	57.10	0.85	59.01	55.19	6%	14%	BULLISH
TLT	ISHARS-20+YTB	158.16	(3.03)	(5.13)	(10.26)	(21.07)	0.23	161.86	164.13	157.57	(0.30)	161.04	154.10	-2%	-4%	BEARISH
BNDX	VANGD-TTL INT B	58.29	(2.47)	(3.44)	(5.01)	(16.32)	(14.17)	58.15	57.64	58.34	0.03	59.82	56.86	0%	1%	BULLISH
HYG	ISHARS-JBX HYCB	85.44	(2.00)	(2.17)	(4.60)	(14.08)	(16.31)	84.54	82.51	83.88	0.38	86.30	81.46	1%	4%	BULLISH



Weekly Stock Screens

Currently, there are 3-different stock screens for you to review. The first is S&P 500 based companies with a "Growth" focus, the second is a "Value" screen on the entire universe of stocks, and the last are stocks that are "Technically" strong and breaking above their respective 50-dma. We have provided the yield of each security and a Piotroski Score ranking to help you find fundamentally strong companies on each screen. ([For more on the Piotroski Score - read this report.](#))

S&P 500 Growth Screen

Ticker	Company	Current Price	Next 3-5 Yr Est EPS Gr rate	5 yr Hist Sales Gr	Div Yield	P/E using 12 mo EPS	Score
AMAT	Appld Matls Inc	69.80	12.66	12.59	1.26	16.70	9.00
AZO	Autozone Inc	1159.73	9.48	3.75	0.00	16.10	8.00
FBHS	Fortune Brd H&S	82.33	9.29	4.99	1.17	20.90	8.00
MSFT	Microsoft Corp	215.44	12.50	13.83	0.95	34.81	8.00
MTD	Mettler-Toledo	1157.87	12.10	5.59	0.00	48.06	8.00
PKI	Perkinelmer Inc	130.64	30.25	8.24	0.21	23.00	8.00
TMO	Thermo Fisher	486.56	18.00	11.58	0.18	30.39	8.00
ADP	Automatic Data	169.43	12.00	6.17	2.15	28.28	7.00
AVY	Avery Dennison	147.62	6.65	4.28	1.57	22.47	7.00
BLL	Ball Corp	94.20	5.00	8.85	0.64	32.94	7.00
CPRT	Copart Inc	117.33	13.00	16.55	0.00	45.65	7.00
CTLT	Catalent Inc	103.44	18.34	12.58	0.00	50.96	7.00
DVA	Davita Inc	107.18	18.26	-6.66	0.00	14.41	7.00
IDXX	Idexx Labs Inc	449.22	15.83	10.64	0.00	78.26	7.00
IT	Gartner Inc -A	153.00	10.00	17.83	0.00	34.08	7.00
KLAC	Kla Corp	233.26	13.64	17.02	1.54	21.42	7.00
MXIM	Maxim Intg Pdts	80.46	10.00	0.36	2.39	32.58	7.00
NVDA	Nvidia Corp	538.27	20.07	22.72	0.12	87.52	7.00
QRVO	Qorvo Inc	146.67	15.77	4.66	0.00	21.89	7.00
SHW	Sherwin William	717.31	10.27	12.94	0.75	30.22	7.00
TER	Teradyne Inc	100.48	16.74	10.61	0.40	22.89	7.00
TGT	Target Corp	159.53	7.22	2.75	1.71	22.73	7.00
UPS	Utd Parcel Svc	163.11	7.90	6.91	2.48	21.27	7.00
WST	West Pharm Svc	289.59	20.47	7.42	0.23	68.46	7.00
AJG	Gallagher Arthu	113.15	11.06	7.24	1.59	25.54	6.00
APH	Amphenol Corp-A	120.21	8.50	9.76	0.83	33.49	6.00
ATVI	Activision Blzd	76.71	15.99	6.56	0.53	23.10	6.00
BLK	Blackrock Inc	659.79	9.03	8.02	2.20	20.61	6.00
CDW	Cdw Corp	135.56	13.10	7.83	1.12	21.45	6.00
DG	Dollar General	212.78	11.09	8.87	0.68	23.13	6.00
DOV	Dover Corp	120.00	11.50	0.15	1.65	21.20	6.00
FDX	Fedex Corp	267.16	12.00	8.62	0.97	23.60	6.00
J	Jacobs Engin Gr	99.26	7.77	5.59	0.77	18.62	6.00
LRCX	Lam Research	418.46	16.49	14.53	1.24	22.69	6.00
MAS	Masco	54.08	16.59	0.85	1.04	18.78	6.00
NVR	Nvr Inc	4149.71	12.96	7.87	0.00	19.13	6.00
PKG	Packaging Corp	126.87	5.00	5.17	2.49	20.60	6.00
RMD	Resmed Inc	212.79	14.53	12.50	0.73	41.72	6.00
RSG	Republic Svcs	100.94	9.40	2.71	1.68	28.92	6.00
TT	Trane Tech Plc	143.39	9.15	3.61	1.48	29.75	6.00
TYL	Tyler Tech Inc	414.18	15.00	13.66	0.00	97.68	6.00
AOS	Smith (Ao) Corp	54.09	9.00	3.17	1.92	27.18	5.00
BBY	Best Buy	114.00	7.72	2.62	1.02	17.78	5.00

Low P/B, High-Value Score, High Dividend Screen

Ticker	Company	Current Price	Price/ Book	ROE 5 Yr Avg	Div Yield	Score
SJM	Smucker Jm	117.85	1.61	11.92	3.05	9
DLX	Deluxe Corp	24.40	2.00	31.49	4.92	8
HPE	Hewlett Pkd Ent	9.67	0.77	11.07	4.96	8
LARK	Landmark Bcp	24.18	0.92	10.12	3.31	8
PEG	Public Sv Entrp	59.18	1.89	11.16	3.31	8
TFC	Truist Finl Cp	46.33	1.01	10.08	3.89	8
TSLX	Sixth St Spclty	18.97	1.12	12.32	8.65	8
VIAC	Viacomcbs Inc	29.25	1.18	44.44	3.28	8
VIACA	Viacomcbs-A	30.50	1.23	44.44	3.15	8
APOG	Apogee Entrprs	24.20	1.21	16.19	3.10	7
BSRR	Sierra Bancorp	20.82	0.94	10.42	3.84	7
CFR	Cullen Frost Bk	78.50	1.21	11.21	3.62	7
CHCO	City Hldgs Co	64.17	1.49	13.27	3.55	7
CMTV	Commnty Bcp Vt	14.39	1.03	12.25	5.28	7
CPF	Central Pac Fin	16.56	0.86	10.07	5.56	7
CRWS	Crown Crafts	6.94	1.56	13.87	4.61	7
CZFS	Citizens Fin Sv	46.31	0.96	11.74	3.97	7
FCBP	First Choice Bc	15.90	0.68	12.00	6.29	7
FGBI	First Guaranty	16.61	0.88	10.07	3.85	7
FISI	Financial Inst	18.93	0.69	10.33	5.49	7
FMNB	Farmers Natl Bc	12.37	1.03	11.01	3.56	7
FNF	Fnf Group	33.59	1.37	14.03	3.93	7
IBCP	Indep Bk Mich	16.37	0.96	11.09	4.89	7
KBAL	Kimball Intl B	10.77	1.61	20.16	3.34	7
LTC	Ltc Properties	36.04	1.82	13.30	6.33	7
PFBC	Preferred Bank	37.08	1.11	15.19	3.24	7
STT	State St Corp	66.90	1.02	12.68	3.11	7
SWM	Schweitzer-Maud	36.54	1.82	19.52	4.82	7
TRST	Trustco Bk -Ny	5.99	1.03	10.90	4.55	7
UBFO	United Sec Bcsh	6.68	0.96	10.41	6.59	7
WTBA	West Bancorp	19.29	1.48	14.69	4.35	7

Aggressive Growth Strategy

Ticker	Company	Current Price	Next 3-5 Yr Est EPS Gr rate	5 yr Hist Sales Gr	Div Yield	P/E F1/ LT EPS Gr	Score
MSCI	Msci Inc-A	389.48	#N/A	10.18	0.80	#N/A	8
MSFT	Microsoft Corp	215.44	12.50	13.83	0.95	2.56	8
CPRT	Copart Inc	117.33	13.00	16.55	-	3.12	7
FICO	Fair Isaac Inc	461.72	#N/A	8.93	-	#N/A	7
IDXX	Idexx Labs Inc	449.22	15.83	10.64	-	4.71	7
NVDA	Nvidia Corp	538.27	20.07	22.72	0.12	3.87	7
QLYS	Qualys Inc	90.47	#N/A	17.75	-	#N/A	7
WST	West Pharm Svc	289.59	20.47	7.42	0.23	3.11	7
BF.B	Brown Forman B	77.83	#N/A	(4.73)	0.90	#N/A	6
REXR	Rexford Ind Rty	49.57	4.46	29.26	1.73	8.53	6
RGEN	Repligen	206.57	30.00	35.13	-	4.80	6
RMD	Resmed Inc	212.79	14.53	12.50	0.73	2.88	6
TYL	Tyler Tech Inc	414.18	15.00	13.66	-	6.66	6

Portfolio / Client Update

The past week was crazy. On Monday, Pfizer announced they might have a vaccine that could be 90% effective. Unfortunately, if you read this week's newsletter, that vaccine is still a very long way off. Nonetheless, the announcement led to a massive rotation into the market's most beaten-up sectors with "*momentum names*" selling off. Then, on Wednesday, the entire trade reversed, and the market spent the week only making a small overall gain and is only 0.50% than it was back at the September highs.



We finally got some "love" in our "value" stocks like CLX, CVS, CVX, and RTX. If we continue to see a relative increase in these value names, we will add some more incrementally. Bonds were also extremely oversold, so our addition to TLT also helped performance this week. Once TLT gets back to overbought, we will reduce the duration and size of our bond holdings and rebalance portfolios to position for 2021.

Portfolio Changes

This past week we made the following changes to portfolios, as we noted in real-time on [RIAPRO.NET](https://riapro.net). **EQUITY & ETF Models:**

"While the Pfizer news caused a couple of days of sector rotation, the reality is that a vaccine is not coming soon. As such, the markets are going to start gravitating back to companies that can grow earnings regardless of the economic environment as people remain working from home and the virus remains a threat. As such we used the pullback in CLX to add to our position. Also, bonds got extremely oversold (3-standard deviations below the 50-dma) which is an ideal setup for a trade."


In Both Portfolios:

- Add 1% to CLX, bringing the total weight up to 3% of the portfolio.
- Add 5% to TLT, bringing the total weight up to 15% of the portfolio.


We have brought equity weights up and reduced our hedges temporarily to participate with the market's advance. Once markets return to more extreme overbought conditions, we will take profits and rebalance risks accordingly. As always, our short-term concern remains the protection of your portfolio. We have now shifted our focus from the election back to the economic recovery and where we go from here. *Lance Roberts CIO*

THE REAL 401k PLAN MANAGER

A Conservative Strategy For Long-Term Investors



Current Portfolio Weighting



Current 401k Allocation Model

5.00% Cash + All Future Contributions

Primary concern is the protection of investment capital

Examples: Stable Value, Money Market, Retirement Reserves

35.00% Fixed Income (Bonds)

Bond Funds reflect the direction of interest rates

Examples: Short Duration, Total Return and Real Return Funds

60.00% Equity (Stocks)

The vast majority of funds track an index.

Therefore, select on ONE fund from each category.

Keep it Simple.

20% Equity Income, Balanced or Conservative Allocation

30% Large Cap Growth (S&P 500 Index)

5% International

5% Mid-Cap

Portfolio Instructions:

Allocation Level To Equities	Recommendation	When To Take Action
Less Than Target Allocation	Hold Current Exposure	Hold Exposure
Equal To Target Allocation	Hold Current Exposure	Hold Exposure
Over Target Allocation	Hold Current Exposure	Hold Exposure


Commentary

The market is now back to short-term overbought conditions. Continue to hold current exposure, but if you are looking to put "money to work" currently, you may want to wait for a correction. Normally, we see mutual funds distribute capital gains in the first two weeks of December which typically leads to a short-term correction. Look for that opportunity to increase allocation models accordingly.

With the election over, the market is going to start expecting more stimulus soon from Washington given the rising number of virus cases. If that fails to appear, there is downside risk to the market. Maintain exposures for now as we head into the end of the year, but if you are close to retirement, or are concerned about the markets, there is nothing wrong with holding extra fixed income or cash in portfolios currently.

If you need help after reading the alert, do not hesitate to [contact me](#).

Model performance is a two-asset model of stocks and bonds relative to the weighting changes made each week in the newsletter. Such is strictly for informational and educational purposes only, and one should not rely on it for any reason. Past performance is not a guarantee of future results. Use at your own risk and peril.



401k Plan Manager Live Model

As an [RIA PRO subscriber](#) (You get your first 30-days free), you can access our live 401k plan manager. Compare your current 401k allocation to our recommendation for your company-specific plan and our on 401k model allocation. You can also track performance, estimate future values based on your savings and expected returns, and dig down into your sector and market allocations. **If you would like to offer our service to your employees at a deeply discounted corporate rate, [please contact me](#).**

RIAPro

Investment Analysis, Research & Data
From The RIA Investment Team

Dashboard

Macro

Ideas

Research

Portfolio

401K- Beta

Symbol

Help

This is the Beta version of 401K. Some Errors are expected ! Click Here to report Issues

My Portfolios

CVS Health

Enter Portfolio Name

Add Portfolio

Delete Portfolio

Rename Portfolio

My Info

Fund Selection

Comparison

Summary

Commentary

My Portfolio

RIAPro Portfolio

RIA PRO MODEL PL

Retirement Income (My Portfolio Annual ROR 9.44 %)

Current account balance	10,000
Estimated Retirement Balance	632,861
Estimated Retirement Balance (Inflation Adj)	620,204
Monthly Income	2,768
Monthly Income (Inflation Adj)	2,713
My Cumulative Contribution	172,934
Employer Cumulative Contribution	103,760

Retirement Income (RiaPro Annual ROR 9.02 %)

Current account balance	10,000
Estimated Retirement Balance	609,786
Estimated Retirement Balance (Inflation Adj)	597,590
Monthly Income	2,667
Monthly Income (Inflation Adj)	2,614
My Cumulative Contribution	172,934
Employer Cumulative Contribution	103,760

My Fund Composition

RIAPro Fund Composition

My Asset Composition

RIAPro Asset Composition